Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients

NCT01801501 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164

Last updated 2020-05-27

No results posted yet for this study

Summary

The purpose of the study is to evaluate the potential role of plasmatic Fibroblast Growth Factor 23 (FGF-23) as a prognosis predictor of clinical outcomes in Critical Care patients.

Conditions

Sponsors & Collaborators

  • University of Chile

    lead OTHER

Principal Investigators

  • Luis Toro, MD · University of Chile Clinical Hospital

  • Luis Michea, MD PhD · University of Chile

  • Carlos Romero, MD · University of Chile Clinical Hospital

Eligibility

Min Age
15 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-04-30
Completion
2018-12-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01801501 on ClinicalTrials.gov